Internal Medicine, Infectious Disease · Houston, TX
NPI
1033216643
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1125 Cypress Station Dr, G1
Houston, TX, 77090
Phone (281) 587-8777
Groups this clinician bills Medicare through
Medicare paid, 2024
$129K
1,411 services
Medicare patients, 2024
241
Average age 73
Drug cost, 2024
$779K
1,352 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Padmavati R Kumashi was code 99233 (hospital e&m - subsequent), 695 times for 148 patients. In total Padmavati R Kumashi billed 1,411 services in 17 codes, and Medicare paid $129K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 695 | 148 | $87.24 | $61K |
| 99214 Office E&M - Established | Office | 286 | 103 | $95.28 | $27K |
| 99223 Hospital E&M - Initial | Facility | 209 | 167 | $127.43 | $27K |
| 99232 Hospital E&M - Subsequent | Facility | 92 | 38 | $59.40 | $5,465 |
| 36589 Venous Catheter Insertion | Office | 23 | 22 | $127.33 | $2,929 |
| 99205 Office E&M - New | Office | 13 | 13 | $169.97 | $2,210 |
By year: 2022 $196K for 44,831 services; 2023 $117K for 11,405 services; 2024 $129K for 1,411 services.
Medicare prescription drug claims, 2024
In 2024, the drug Padmavati R Kumashi prescribed most often to Medicare patients was Meropenem, with 113 prescriptions and refills. In total Padmavati R Kumashi wrote 1,352 Medicare prescriptions that cost $779K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Meropenem Generic | 113 | 113 | 36 | $29K |
| Daptomycin Generic | 89 | 89 | 18 | $122K |
| Ciprofloxacin Hcl Generic | 71 | 77 | 37 | $978 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 70 | 70 | Under 11 | $266K |
| Doxycycline Hyclate Generic | 62 | 89 | 29 | $1,574 |
| Ceftriaxone Ceftriaxone Sodium | 57 | 57 | 15 | $14K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 53 | 82 | 21 | $1,114 |
| Vancomycin Hcl Generic | 42 | 42 | 17 | $6,394 |
| Methenamine Hippurate Generic | 42 | 86 | 14 | $3,513 |
| Gentamicin Sulfate Gentamicin Sulfate/Pf | 40 | 40 | Under 11 | $4,948 |
| Fluconazole Generic | 38 | 46 | 24 | $703 |
| Cefdinir Generic | 35 | 53 | 18 | $1,786 |
| Cefepime Hcl Generic | 35 | 35 | 12 | $8,369 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 27 | 27 | Under 11 | $107K |
| Cephalexin Generic | 27 | 47 | Under 11 | $1,182 |
Brand drugs: 158 claims; generic drugs: 1,194 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Padmavati R Kumashi were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.